Abstract A015: Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer
Authors: John Lambert, Mark Devine, Anthony Bishop
Published: 2022-11-15
DOI:
10.1158/1538-7445.panca22-a015
Source:
Full article
Abstract
Abstract